AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19447835 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous reperfusion (SR) in non-diabetic patients
Number of subjects: 4944
Study 19447835 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous reperfusion (SR) in diabetic patients
Number of subjects: 4944
Study 19447835 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diabetic patients with normoglycaemia
Number of subjects: 4944
Study 19447835 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with normoglycaemia
Number of subjects: 4944
Study 17097398 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retapamulin ointment 1% (twice daily for 5 days)
Number of subjects: 0
Study 17097398 — intervention group
Group type: COMPARATOR
Intervention: Oral cephalexin (500 mg twice daily for 10 days)
Number of subjects: 0
Study 14984435 — intervention group
Group type: EXPERIMENTAL
Intervention: TGZ 600 mg daily
Number of subjects: 24
Study 14984435 — intervention group
Group type: EXPERIMENTAL
Intervention: TGZ 200 mg daily
Number of subjects: 24
Study 14984435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11318049 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related potentials (ERPs) recorded during a discrimination task with cued target location and response.
Number of subjects: 0
Study 11318049 — intervention group
Group type: COMPARATOR
Intervention: Cued target location and response expectancy.
Number of subjects: 0
Study 9524792 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (100 mg every six hours for an average of four days)
Number of subjects: 49
Study 9524792 — intervention group
Group type: COMPARATOR
Intervention: Paromomycin (125 mg every six hours for an average of four days)
Number of subjects: 49
Study 9524792 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 49
Study 9524792 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 49
Study 8292061 — intervention group
Group type: EXPERIMENTAL
Intervention: Eryfer 100 (100 mg Fe++)
Number of subjects: 16
Study 8292061 — intervention group
Group type: COMPARATOR
Intervention: Eryfer (50 mg Fe++)
Number of subjects: 16
Study 3557739 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand A of furosemide
Number of subjects: 7
Study 3557739 — intervention group
Group type: COMPARATOR
Intervention: Brand B of furosemide
Number of subjects: 7
Study 29371381 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled diesel exhaust (DE) combined with allergen exposure
Number of subjects: 0
Study 29371381 — intervention group
Group type: COMPARATOR
Intervention: Inhaled diesel exhaust (DE) alone
Number of subjects: 0
Study 29371381 — intervention group
Group type: COMPARATOR
Intervention: Allergen exposure alone
Number of subjects: 0
Study 29371381 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 0
Study 26551230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 38
Study 26551230 — intervention group
Group type: COMPARATOR
Intervention: Support Group
Number of subjects: 38
Study 24560541 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (Merck Ad5 gag/pol/nef subtype B HIV‐1 preventive vaccine)
Number of subjects: 801
Study 24560541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 801
Study 24560541 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 801
Study 22563210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem, 1 g once daily
Number of subjects: 271
Study 22563210 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone, 2 g once daily
Number of subjects: 271
Study 22563210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 271
Study 22563210 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 271
Study 22563210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem and Ceftriaxone
Number of subjects: 271
Study 20925543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (5571 patients)
Number of subjects: 11140
Study 20925543 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control (5569 patients)
Number of subjects: 11140
Study 18179827 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% ropivacaine hydrochloride soaked swabs
Number of subjects: 41
Study 18179827 — intervention group
Group type: COMPARATOR
Intervention: Saline-soaked swabs
Number of subjects: 41
Study 16170477 — intervention group
Group type: EXPERIMENTAL
Intervention: Polanight (PN)
Number of subjects: 58
Study 16170477 — intervention group
Group type: COMPARATOR
Intervention: Opalescence (OP)
Number of subjects: 58
Study 12455806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin 1 gm every 8 hours for 3 days, then oral cephalexin 500 mg every 6 hours for 4 days
Number of subjects: 97
Study 12455806 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 97
Study 12455806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin followed by oral cephalexin
Number of subjects: 97
Study 12455806 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 10348767 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1 g orally once on the first day, followed by 500 mg orally once daily for the next 6 days
Number of subjects: 123
Study 10348767 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg orally twice daily for 7 days
Number of subjects: 123
Study 7589012 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) 20 mg i.v. bolus
Number of subjects: 31
Study 7589012 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.15 IU kg-1)
Number of subjects: 31
Study 7589012 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 31
Study 2031508 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU), 1,200 mg/m2 i.v. infusion over 2 h
Number of subjects: 125
Study 2031508 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), 200 mg/m2 i.v. (push injection), followed 20 h later by 5-FU, 1,200 mg/m2 i.v. infusion over 2 h, plus calcium leucovorin (LV), 25 mg i.m. every 6 h for eight doses beginning 24 h after MTX administration
Number of subjects: 125
Study 2031508 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 125
Study 2031508 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) followed by 5-FU and LV
Number of subjects: 125
Study 7146823 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium‐heparin (5000 IU every 12 h for at least 2 weeks)
Number of subjects: 30
Study 7146823 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K (for 15 days) followed by subcutaneous calcium‐heparin (5000 IU every 12 h for at least 2 weeks)
Number of subjects: 30
Study 7146823 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium‐heparin (5000 IU every 12 h for at least 2 weeks) started immediately
Number of subjects: 30
Study 6375891 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization treatment with tyrosine-adsorbed Dermatophagoides pteronyssinus antigen
Number of subjects: 0
Study 6375891 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 6375891 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization treatment
Number of subjects: 0
Study 29858421 — intervention group
Group type: EXPERIMENTAL
Intervention: Red LED phototherapy
Number of subjects: 0
Study 29858421 — intervention group
Group type: EXPERIMENTAL
Intervention: Amber LED phototherapy
Number of subjects: 0
Study 26508309 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1000mg orally once daily plus prednisone 5mg orally twice daily
Number of subjects: 2184
Study 26508309 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 2184
Study 25573734 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloids (n = 57)
Number of subjects: 115
Study 25573734 — intervention group
Group type: COMPARATOR
Intervention: Colloids (n = 58)
Number of subjects: 115
Study 22131224 — intervention group
Group type: EXPERIMENTAL
Intervention: CE1 (2 sets of 6 exercises at 80% 1RM followed by 30 min of cycle ergometer exercise at 50% VO2peak)
Number of subjects: 21
Study 22131224 — intervention group
Group type: EXPERIMENTAL
Intervention: CE2 (2 sets of 6 exercises at 80% 1RM followed by 30 min of cycle ergometer exercise at 65% VO2peak)
Number of subjects: 21
Study 22131224 — intervention group
Group type: EXPERIMENTAL
Intervention: CE3 (2 sets of 6 exercises at 80% 1RM followed by 30 min of cycle ergometer exercise at 80% VO2peak)
Number of subjects: 21
Study 22131224 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL 60 min of rest)
Number of subjects: 21
Study 20353449 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer-administered Child-OIDP
Number of subjects: 177
Study 20353449 — intervention group
Group type: COMPARATOR
Intervention: Self-administered Child-OIDP
Number of subjects: 177
Study 18419350 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine-stavudine
Number of subjects: 96
Study 18419350 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine-lamivudine
Number of subjects: 96
Study 18419350 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial haplogroup J
Number of subjects: 96
Study 15787627 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Number of subjects: 9
Study 15787627 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange + Continuous Hemodiafiltration (PE + CHDF)
Number of subjects: 9
Study 11936482 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0
Study 11936482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 11936482 — intervention group
Group type: COMPARATOR
Intervention: Both treatments pooled
Number of subjects: 0
Study 10086434 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methadone (80 to 100 mg)
Number of subjects: 192
Study 10086434 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose methadone (40 to 50 mg)
Number of subjects: 192
Study 8665532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloserine treatment (various dosages)
Number of subjects: 40
Study 8665532 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 40
Study 2206016 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment
Number of subjects: 130
Study 2206016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 7004474 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg orally nightly for 1 week
Number of subjects: 13
Study 7004474 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg rectally nightly for 1 week
Number of subjects: 13
Study 7004474 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 13
Study 7004474 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (oral and rectal)
Number of subjects: 13
Study 7004474 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (oral)
Number of subjects: 13
Study 7004474 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (rectal)
Number of subjects: 13
Study 30444191 — intervention group
Group type: EXPERIMENTAL
Intervention: Grid Laser Photocoagulation (LAS)
Number of subjects: 60
Study 30444191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (RAN)
Number of subjects: 60
Study 30444191 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Treatment (COM)
Number of subjects: 60
Study 29940289 — intervention group
Group type: EXPERIMENTAL
Intervention: High abrasive slurry with 275 ppm fluoride
Number of subjects: 96
Study 29940289 — intervention group
Group type: EXPERIMENTAL
Intervention: High abrasive slurry with 1250 ppm fluoride
Number of subjects: 96
Study 29940289 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride at 275 ppm with high abrasive slurry after 7 days
Number of subjects: 96
Study 29940289 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing frequency 1×/day with high abrasive slurry after 7 days
Number of subjects: 96
Study 29940289 — intervention group
Group type: COMPARATOR
Intervention: Brushing frequency 3×/day with high abrasive slurry
Number of subjects: 96
Study 25159038 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm recurrence volumetry with HydroSoft coils (HSC)
Number of subjects: 297
Study 25159038 — intervention group
Group type: COMPARATOR
Intervention: Aneurysm recurrence volumetry with bare platinum coils (BPC)
Number of subjects: 297
Study 25159038 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment with HydroSoft coils (HSC)
Number of subjects: 297
Study 25159038 — intervention group
Group type: COMPARATOR
Intervention: Visual assessment with bare platinum coils (BPC)
Number of subjects: 297
Study 25159038 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm recurrence volumetry for aneurysms smaller than the sample median
Number of subjects: 297
Study 25159038 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment for aneurysms smaller than the sample median
Number of subjects: 297
Study 23273827 — intervention group
Group type: EXPERIMENTAL
Intervention: Program to promote play with plush toys during the postsurgical period
Number of subjects: 0
Study 23273827 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard attention without specific treatment
Number of subjects: 0
Study 22331954 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus docetaxel (sunitinib 37.5 mg/d, days 2 to 15 every 3 weeks; docetaxel 75 mg/m2, day 1 every 3 weeks)
Number of subjects: 593
Study 22331954 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone (100 mg/m2 every 3 weeks)
Number of subjects: 593
Study 22331954 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus docetaxel
Number of subjects: 593
Study 22331954 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 593
Study 19951008 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 73
Study 19951008 — intervention group
Group type: COMPARATOR
Intervention: Dan‐shen combined with low‐molecular weight dextrose
Number of subjects: 73
Study 16973657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin, Tacrolimus, or p55TNFr-Ig (anti-TNF agent)
Number of subjects: 37
Study 15815820 — intervention group
Group type: EXPERIMENTAL
Intervention: BioZ monitor (impedance cardiography)
Number of subjects: 186
Study 15815820 — intervention group
Group type: COMPARATOR
Intervention: Physician assessment of CI and TFC
Number of subjects: 186
Study 11223695 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium diet (< 600 mg/day)
Number of subjects: 35
Study 11223695 — intervention group
Group type: COMPARATOR
Intervention: Other patients (not on low calcium diet)
Number of subjects: 35
Study 9393299 — intervention group
Group type: EXPERIMENTAL
Intervention: TUR plus BCG therapy
Number of subjects: 48
Study 9393299 — intervention group
Group type: COMPARATOR
Intervention: TUR
Number of subjects: 48
Study 7896386 — intervention group
Group type: EXPERIMENTAL
Intervention: Folifer and calcium tablets supplied from second trimester till delivery along with regular medical supervision and nutrition education.
Number of subjects: 66
Study 7896386 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) with no supplementation.
Number of subjects: 66
Study 3630961 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement of 100 g/d of mackerel
Number of subjects: 0
Study 3630961 — intervention group
Group type: COMPARATOR
Intervention: Meat supplement
Number of subjects: 0
Study 31220021 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tendon repair
Number of subjects: 103
Study 31220021 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 103
Study 28340086 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (10 sessions with licensed massage therapists)
Number of subjects: 104
Study 28340086 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 104
Study 26043884 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART for 96 weeks (ART-96W)
Number of subjects: 268
Study 26043884 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART until clinical or immunological progression (ART-Def)
Number of subjects: 268
Study 26043884 — intervention group
Group type: EXPERIMENTAL
Intervention: ART started between 12 and 24 weeks of age
Number of subjects: 268
Study 26043884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative viral load to week 84
Number of subjects: 268
Study 23648617 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-guided passive stretching and active movement training
Number of subjects: 24
Study 23648617 — intervention group
Group type: COMPARATOR
Intervention: Instructed exercise program at home (control group)
Number of subjects: 24
Study 21040773 — intervention group
Group type: EXPERIMENTAL
Intervention: So-cheong-ryong-tang (SCRT)
Number of subjects: 480
Study 21040773 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeon-gyo-pae-dok-san (YPS)
Number of subjects: 480
Study 21040773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 21040773 — intervention group
Group type: EXPERIMENTAL
Intervention: SCRT and YPS
Number of subjects: 480
Study 19190553 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 W laser
Number of subjects: 40
Study 19190553 — intervention group
Group type: COMPARATOR
Intervention: 25 W laser
Number of subjects: 40
Study 17083652 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg of sublingual misoprostol with vaginal placebo (n = 70)
Number of subjects: 140
Study 17083652 — intervention group
Group type: COMPARATOR
Intervention: 25 microg of vaginal misoprostol with sublingual placebo (n = 70)
Number of subjects: 140
Study 17083652 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg of sublingual misoprostol
Number of subjects: 140
Study 17083652 — intervention group
Group type: COMPARATOR
Intervention: 25 microg of vaginal misoprostol
Number of subjects: 140
Study 15313947 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang 1200 mg/d
Number of subjects: 50
Study 15313947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11704602 — intervention group
Group type: EXPERIMENTAL
Intervention: LTE(4)
Number of subjects: 15
Study 11704602 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen
Number of subjects: 15
Study 11704602 — intervention group
Group type: EXPERIMENTAL
Intervention: LTD(4)
Number of subjects: 15
Study 11704602 — intervention group
Group type: COMPARATOR
Intervention: Diluent
Number of subjects: 15
Study 8935811 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (630-910 mg/day)
Number of subjects: 11
Study 8935811 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (1100 mg/day)
Number of subjects: 11
Study 8935811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1589668 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 750 mg b.i.d. for 7 days
Number of subjects: 278
Study 1589668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 1589668 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 278
Study 4083099 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic drink
Number of subjects: 14
Study 4083099 — intervention group
Group type: COMPARATOR
Intervention: Orange juice
Number of subjects: 14
Study 31048405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocellular lipid (IMCL) CH2:CH3 ratio in lipodystrophic subjects
Number of subjects: 71
Study 31048405 — intervention group
Group type: COMPARATOR
Intervention: Intramyocellular lipid (IMCL) CH2:CH3 ratio in athletes
Number of subjects: 71
Study 31048405 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted IMCL CH2:CH3 (CH2:CH3adj)
Number of subjects: 71
Study 31048405 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2max
Number of subjects: 71
Study 29627512 — intervention group
Group type: EXPERIMENTAL
Intervention: School garden intervention (n=24)
Number of subjects: 2768
Study 29627512 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n=22)
Number of subjects: 2768
Study 27855341 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) - six month supervised aerobic and resistance training intervention (three days/week)
Number of subjects: 50
Study 27855341 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 50
Study 24833646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonas intervention (14 sessions)
Number of subjects: 39
Study 24833646 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 39
Study 22703885 — intervention group
Group type: EXPERIMENTAL
Intervention: Young Citizens Program (intervention)
Number of subjects: 24
Study 22703885 — intervention group
Group type: COMPARATOR
Intervention: Control group (received the same curriculum after the trial)
Number of subjects: 24
Study 20424027 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval practice (repeatedly recalling selected items from a previously studied list)
Number of subjects: 0
Study 20424027 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval practice with nocturnal sleep during the retention interval
Number of subjects: 0
Study 20424027 — intervention group
Group type: COMPARATOR
Intervention: Retrieval practice without nocturnal sleep
Number of subjects: 0
Study 18298357 — intervention group
Group type: EXPERIMENTAL
Intervention: Night splint worn with the affected ankle at plantargrade, 7 nights per week for 4 weeks
Number of subjects: 30
Study 18298357 — intervention group
Group type: COMPARATOR
Intervention: Standing on a tilt table for 30 min with the ankle at maximum dorsiflexion, 5 times per week for 4 weeks
Number of subjects: 30
Study 15985471 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 2931
Study 12203058 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture, group H (3.45 +/- 0.07 g/kg per day)
Number of subjects: 30
Study 12203058 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture, group M (2.59 +/- 0.07 g/kg per day)
Number of subjects: 30